Keros Therapeutics, Inc. current report, 28 January 2022

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on January 28, 2022, reporting events occurring on January 31, 2022. The filing discloses the appointment of a new executive officer and the terms of his employment agreement.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance.

Material Changes

The primary material change reported is the appointment of Christopher Rovaldi as Chief Operating Officer (COO), effective February 1, 2022. Mr. Rovaldi joins the company with over 20 years of experience in program and portfolio management for biologics and small molecules, having previously served as a consultant to the company and held senior roles at Acceleron Pharma, Idenix Pharmaceuticals, and Cubist Pharmaceuticals.

Management Commentary, Risks, and Unusual Items

Compensatory Arrangements:

  • Base Salary: $470,000 annually.
  • Discretionary Bonus: Target amount equal to 50% of the annual base salary.
  • Equity Grant: Stock option to purchase up to 100,000 shares of common stock. The exercise price will be the closing price on the grant date.
  • Vesting Schedule: 25% vests on the first anniversary of the vesting commencement date; the remaining 75% vests quarterly (6.25% per quarter) over the subsequent three years.
Severance Provisions:
  • Termination without Cause/Good Reason (No Change of Control): 9 months of base salary and COBRA premiums for up to 9 months.
  • Termination without Cause/Good Reason (Within 12 months of Change of Control): 12 months of base salary, acceleration of all unvested equity awards, 100% of the target bonus for the year of termination, and COBRA premiums for up to 12 months.
Other Terms:
  • Employment is "at-will."
  • Subject to a 12-month non-competition and non-solicitation covenant post-termination.
  • Standard indemnification agreement to be executed.

Investor Verification Checklist

  • Verify the exact grant date and exercise price for the 100,000 stock options once the grant is finalized.
  • Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
  • Confirm the vesting commencement date to calculate the precise vesting schedule.
  • Assess the impact of the new COO's background on the company's clinical development pipeline and operational strategy.